Direct answer
42 CFR § 483.45(c) requires a licensed pharmacist to review each nursing home resident’s drug regimen at least monthly, including the medical chart. Any irregularities must be documented on a separate written report sent to the attending physician, medical director, and director of nursing, and those reports must be acted upon. Facilities also need policies with time frames and urgent-escalation steps.
Key takeaways
- A monthly pharmacist review is required for every resident, not only high-risk cases.
- Irregularities must go on a separate written report to the physician, medical director, and DON.
- The attending physician must document review, action taken, or the rationale for no change.
- F756 review quality and F757 unnecessary-drug control are operationally linked.
- The real survey risk is not just finding an issue late. It is failing to prove who saw it, when they acted, and what changed.
Monthly drug regimen review looks straightforward on paper. In real skilled nursing operations, it rarely is. A pharmacist identifies an irregularity, the note gets routed late, the physician response sits in a charting gap, the DON assumes someone else closed the loop, and the facility discovers the weakness when surveyors ask for proof.
That is why 42 CFR § 483.45(c) matters operationally. This rule is not just about having a consultant pharmacist. It is about whether the facility can show a repeatable monthly process for reviewing each resident’s regimen, reporting irregularities, acting on them, and documenting what happened next.
For Administrators, DONs, and compliance leaders, the exposure usually is not one missed recommendation in isolation. It is the combination of late review, weak routing, unclear ownership, and inconsistent physician follow-through. That is where F756 issues start to bleed into F757 unnecessary-drug risk and broader survey-readiness problems.
What does 42 CFR § 483.45(c) actually require?
Under 42 CFR § 483.45(c), the drug regimen of each resident must be reviewed at least once a month by a licensed pharmacist, and that review must include the resident’s medical chart. If the pharmacist identifies an irregularity, the irregularity must be documented on a separate written report and sent to the attending physician as well as the facility’s medical director and director of nursing.
The rule also requires action. The attending physician must document in the medical record that the irregularity was reviewed and what action, if any, was taken. If there is no medication change, the physician should document the rationale. The facility must also maintain policies and procedures for the monthly drug regimen review process, including time frames for each step and what happens when the pharmacist identifies an urgent issue.
- Every resident requires at least one monthly drug regimen review by a licensed pharmacist.
- The review must include the medical chart, not only the medication list.
- Irregularities must be documented on a separate written report.
- That report must be sent to the attending physician, medical director, and DON.
- The physician must document review and resulting action or rationale.
- Facility policy must define timing and urgent-escalation steps.
Why do F756 and F757 usually break in the workflow, not just in the chart?
F756 focuses on the review-and-reporting process. F757 focuses on whether each resident’s regimen is free from unnecessary drugs. In practice, facilities do not get clean separation between those two tags. If the pharmacist flags duplicate therapy, excessive duration, inadequate monitoring, poor indication, or adverse consequences and the report is not acted on cleanly, a review-process problem quickly becomes an unnecessary-drug problem.
That is the core operator lesson. A facility can have a contracted pharmacist, scheduled monthly reviews, and even thoughtful recommendations. If the routing and closeout steps are loose, leadership still ends up exposed. Surveyors do not just want to know whether the pharmacist looked. They want to know whether the facility acted.
What counts as an irregularity in a skilled nursing monthly drug review?
The regulation says irregularities include, but are not limited to, drugs that meet the criteria for an unnecessary drug under 42 CFR § 483.45(d). That includes medications used in excessive dose, for excessive duration, without adequate monitoring, without adequate indication, in the presence of adverse consequences that suggest reduction or discontinuation, or in problematic combination with other concerns.
Operationally, irregularities often show up as patterns rather than one dramatic event. A resident stays on a medication after the original trigger resolves. PRN use becomes routine without a clean reassessment trail. Monitoring orders exist, but the results are not easy to connect back to the medication decision. A recommendation is documented, but nobody can show the physician response date or whether the care plan changed.
- Duplicate drug therapy or dose intensity that no longer matches the resident’s condition.
- Medication continued longer than the documented indication supports.
- Monitoring gaps, including labs, behavior tracking, or adverse-effect follow-up.
- A pharmacist recommendation that never receives a documented physician response.
- A resident-status change that should trigger closer review, but ownership is unclear.
How should a nursing home run the F756 monthly drug regimen review workflow?
High-functioning facilities do not treat monthly drug review as a pharmacy inbox event. They run it like a controlled cross-functional workflow with named owners, defined deadlines, and visible exception status.
A practical workflow usually looks like this:
- Step 1: Maintain a resident census and chart-access process so the pharmacist can complete a monthly review for every resident on time.
- Step 2: Require the pharmacist’s findings to be captured on a separate written irregularity report when concerns are identified.
- Step 3: Route each irregularity report the same day to the attending physician, medical director, and DON.
- Step 4: Assign a facility owner to track open recommendations, due dates, and urgent escalations.
- Step 5: Confirm the physician documented review, action taken, or rationale for no change in the resident record.
- Step 6: Verify any resulting order change, monitoring change, care-plan update, or staff communication was actually completed.
- Step 7: Close the loop with dated proof so the facility can show survey-ready follow-through, not just a recommendation file.
What do surveyors and operators both care about most?
Surveyors care about whether the regulatory steps happened. Operators care about whether the process is dependable when the building is busy. Those priorities overlap more than many teams think. The risky facilities are not always the ones with no process. They are often the ones with a partially manual process that works until a hospital return, behavior change, medication add-on, vacation coverage gap, or physician-response delay exposes the weak link.
This is where manual workflows start to break. Recommendations live in email. Follow-up lives in sticky notes or a binder. The DON has partial visibility. The physician answer is somewhere in the chart, but not connected to the recommendation tracker. By the time leadership reconstructs the timeline, the cost is already in survey stress, extra chart review, and credibility loss.
How do psychotropic and unnecessary-drug rules raise the stakes?
CMS guidance in Appendix PP ties medication regimen review to the broader unnecessary-drug and psychotropic-medication framework. That matters because psychotropic use, monitoring, PRN use, gradual dose reduction expectations when applicable, and documentation of clinical indication all increase the need for disciplined review and follow-through.
Facilities do not need to turn every pharmacist note into a crisis. They do need a workflow that separates routine recommendations from urgent resident-protection issues, escalates the urgent items immediately, and gives leadership confidence that medication-related irregularities will not disappear between pharmacy, nursing, and the prescriber.
What should Administrators and DONs fix first?
If your facility wants the fastest improvement, start with visibility and ownership rather than with more meetings. Most buildings already know who the pharmacist is and when the monthly review should happen. The larger failure point is proving that every flagged issue moved from identification to physician review to completed action.
- Define one owner for open irregularity tracking, even if multiple departments help close the loop.
- Set internal turnaround expectations for routine items and separate rules for urgent issues.
- Standardize where physician rationale is documented when no medication change is made.
- Require evidence that downstream tasks were completed, such as order changes, monitoring updates, and care-plan communication.
- Review trends monthly so repeated medication-review failures become a QAPI operating issue, not a survey surprise.
Where ePeople AI fits
ePeople AI is not legal counsel and does not replace clinical judgment. It is the operating layer that helps skilled nursing teams keep time-sensitive workflows from getting lost in handoffs. For monthly drug regimen review, that means surfacing open irregularities, routing follow-up to the right owners, tracking whether documentation actually came back, and keeping exception status visible before survey week.
If your monthly pharmacist review process still depends on inbox chasing, scattered logs, and memory, this is exactly where late visibility becomes expensive. ePeople AI helps facilities turn cross-functional follow-up into a cleaner action queue so the team can respond faster and stay audit-ready.
